



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/05/08
(87) Date publication PCT/PCT Publication Date: 2018/11/15
(85) Entrée phase nationale/National Entry: 2019/11/06
(86) N° demande PCT/PCT Application No.: US 2018/031674
(87) N° publication PCT/PCT Publication No.: 2018/208837
(30) Priorités/Priorities: 2017/05/08 (US62/503,060);
2017/10/31 (US62/579,460)

(51) Cl.Int./Int.Cl. *A61K 48/00* (2006.01),
A61P 35/00 (2006.01), *C07K 19/00* (2006.01),
C12N 15/113 (2010.01), *C12N 15/63* (2006.01)

(71) Demandeur/Applicant:
PRECISION BIOSCIENCES, INC., US

(72) Inventeurs/Inventors:
HUX, JOANN, US;
MARTIN, AARON, US;
JANTZ, DEREK, US;
BEARD, CLAYTON, US

(74) Agent: MBM INTELLECTUAL PROPERTY LAW LLP

(54) Titre : MOLECULES D'ACIDE NUCLEIQUE CODANT POUR UN RECEPTEUR D'ANTIGENE MODIFIE ET
MOLECULE D'ACIDE NUCLEIQUE INHIBITRICE ET LEURS METHODES D'UTILISATION
(54) Title: NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY
NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF




FIGURE 1

(57) **Abrégé/Abstract:**

The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule. The present disclosure further relates to nucleic acids, DNA constructs, vectors, pharmaceutical compositions, genetically-modified cells, and methods of treatment that utilize the nucleic acid molecules of the invention.